AdvanCell is a clinical-stage radiopharmaceutical company developing targeted alpha therapies using proprietary ²¹²Pb production technology to treat various cancers, including prostate and pancreatic. This approach aims to enhance patient survival and quality of life by delivering precise radiation to tumor cells while minimizing damage to surrounding healthy tissue.

Aetion offers a cloud‑native platform that ingests heterogeneous health data (EHR, claims, registries) and provides guardrailed ETL pipelines, validated causal‑inference analytics, and AI‑driven synthetic data generation to produce regulatory‑ready real‑world evidence. Its visual dashboards, APIs, and compliance controls enable biopharma, med‑tech firms, and regulators to generate reproducible evidence in weeks rather than months.

Atalanta Therapeutics is developing di-siRNA technology to utilize RNA interference for gene silencing, targeting the underlying mechanisms of neurodegenerative diseases such as Huntington's disease. This approach aims to provide effective treatment options that address the urgent need for interventions in central nervous system disorders.

Empatica develops FDA-cleared wearable devices and a health monitoring platform that continuously collects clinical-quality health data and digital biomarkers from everyday life. This technology enables researchers and clinicians to monitor conditions such as epilepsy and movement disorders, enhancing data collection for clinical trials and real-world health insights.

Escient Pharmaceuticals develops first-in-class oral therapeutics targeting Mas-related G protein-coupled receptors (MRGPRs) to treat neurosensory-inflammatory disorders such as chronic urticaria and cholestatic pruritus. Their approach utilizes small molecule antagonists to address the underlying mechanisms of neurogenic inflammation, providing potential new treatment options for patients with limited existing therapies.

Evidation develops a health data analytics platform that collects and analyzes high-frequency behavior data from sensors, devices, and other sources to generate actionable health insights. The platform enables individuals and organizations to understand and influence daily behaviors that impact health outcomes, while allowing users to control their data and earn rewards for healthy activities.

Expedition Therapeutics is developing EXPD-101, an oral, once‑daily DPP1 inhibitor that selectively blocks neutrophil serine protease activation to reduce airway tissue damage and disease progression in COPD and other neutrophil‑driven respiratory conditions. The drug is designed for high potency, favorable pharmacokinetics, and a strong safety profile, with Phase 1 tolerability data and a global Phase 2 trial underway. It targets pharmaceutical partners, clinical researchers, and healthcare providers seeking disease‑modifying therapies for COPD, bronchiectasis, neutrophilic asthma, and related diseases.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company developing losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy (FSHD), and FTX-6058, designed to enhance fetal hemoglobin expression for treating sickle cell disease and beta-thalassemia. These therapies aim to address the unmet medical needs of patients suffering from these debilitating genetic disorders.

Glycomine is developing GLM101, a mannose-1-phosphate replacement therapy currently in clinical trials for PMM2-CDG, a rare genetic disease caused by glycosylation defects. This therapy aims to restore the missing biochemical function, offering potential disease modification rather than merely symptomatic relief.

Granite Bio develops first-in-class therapeutic antibodies targeting the fundamental biology of inflammation, autoimmunity, and fibrosis. The company's pipeline includes assets designed to selectively deplete pathogenic cells, such as GRT-001 which targets pro-inflammatory monocytes. These novel mechanisms aim to provide efficacious treatment options where current therapies are lacking for chronic inflammatory diseases.

I2o Therapeutics develops oral formulations of long-acting GLP-1 receptor agonists and other peptide therapies to treat cardio-renal-metabolic diseases. Their approach aims to provide safer and more effective treatment options for patients with these complex conditions.

Icosavax is developing virus-like particle (VLP) vaccines to protect vulnerable older adults from multiple respiratory viruses. This approach aims to enhance immune response, increase coverage against viral mutations, and reduce side effects compared to traditional vaccine methods.

Kymera Therapeutics specializes in targeted protein degradation to develop therapeutics that directly eliminate disease-causing proteins. This approach enables the treatment of a wide range of diseases by addressing the underlying mechanisms of illness, offering new options for patients with unmet medical needs.

Lava Therapeutics develops a bispecific antibody platform, Gammabody®, that engages Vγ9Vδ2 T cells to target and kill cancer cells while enhancing immune responses. This technology aims to improve tumor recognition and treatment efficacy, potentially leading to better patient survival outcomes.

This company develops antibody-drug conjugates (ADCs) that precisely target and treat autoimmune and inflammatory diseases. Their proprietary ADC platform aims to deliver enhanced efficacy and safety, creating innovative therapies for unmet needs in immunology and inflammation.

Ligo Biosciences builds deep‑learning generative models that design novel enzymes for the chemical industry. By training on natural protein sequences and structures, their platform creates catalysts that can accelerate and scale the synthesis of materials and products, reducing reliance on traditional chemical processes. The company monetizes access to its enzyme‑design platform through licensing and service agreements with industrial partners seeking more efficient biocatalytic solutions.

Matchpoint Therapeutics utilizes chemoproteomics and machine learning to discover precision small molecule covalent medicines that target disease-causing proteins in immune diseases. By forming irreversible bonds with specific protein targets, their approach enhances potency and selectivity, enabling the treatment of conditions previously deemed untreatable with traditional small molecule therapies.

Muna Therapeutics develops therapies aimed at slowing or halting neurodegenerative diseases, specifically targeting the underlying mechanisms of Alzheimer’s and Parkinson’s. The company utilizes advanced drug discovery techniques to create disease-modifying treatments that address the progressive nature of these conditions.

NodThera is developing NLRP3 inflammasome inhibitors to target chronic inflammatory diseases at their source, including obesity, cardiometabolic, and neurodegenerative conditions. By focusing on this upstream catalyst of inflammation, NodThera aims to provide effective treatments that improve patient outcomes and quality of life.

Nura Bio is developing neuroprotective therapies that target axon degeneration and neuroimmune regulation to preserve neuronal integrity in patients with neurological diseases. By addressing the underlying mechanisms of these disorders, the company aims to halt disease progression and provide hope for effective treatments.

Nuvig Therapeutics develops next‑generation immune modulators that activate endogenous regulatory pathways to restore immune tolerance without broad immunosuppression. Its lead candidate, NVG‑2089, is an engineered IgG1 Fc fragment that engages Type II Fcγ receptors, and the company’s BESTech™ platform extends this tolerogenic Fc into multi‑functional antibodies for a range of autoimmune and chronic inflammatory diseases.

Omass Therapeutics offers a proprietary platform that combines custom biochemistry, native mass spectrometry, and specialized chemistry to study membrane proteins and intracellular complexes in a near‑physiological, cell‑free environment. The technology quantifies binding affinities, kinetics, and functional outcomes, enabling pharmaceutical and biotech R&D teams to identify and optimize small‑molecule leads, including low‑affinity and allosteric binders, for orphan and immune‑mediated diseases.

Ovid Therapeutics develops targeted small molecule therapies aimed at reducing seizures in patients with epilepsy and other neurological conditions. Their approach focuses on unique mechanisms of action to enhance safety and tolerability, ultimately improving the quality of life for affected individuals and families.

Q32 Bio develops targeted biotherapeutics that re-regulate immune function to treat severe autoimmune and inflammatory diseases. Their lead candidates, Bempikibart and ADX-097, are designed to modulate adaptive and innate immune responses, respectively, addressing conditions such as atopic dermatitis and ANCA-Associated Vasculitis.